Zynerba Pharmaceuticals Stock News

Analysts say these are penny stocks to buy right now. The post Top Penny Stocks To Buy The Dip According To Analysts In September appeared first on Penny Stocks to Buy, Picks, News and Information | P

Zynerba Pharmaceuticals Inc has announced the initiation of a pivotal, multinational randomized, double-blind, placebo-controlled, multiple-center (RECONNECT) Phase 3 trial to evaluate the efficacy an

Trial will evaluate the efficacy and safety of Zygel in children and adolescents with  Fragile X Syndrome

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presented data from the Phase 2 BRIGHT trial of Zygel in children and adolescents with autism spectrum disorder (ASD) over a longer-term, 38-week treatment

Zynerba Pharmaceuticals Inc. has presented data from the Phase 2 BRIGHT trial describing the tolerability and efficacy of its Zygel transdermal cannabinoid therapy in children and adolescents with aut

DEVON, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare

Zynerba Pharmaceuticals Inc told investors that an article in the Journal of the American Medical Association (JAMA) Network Open had described the results of the company's open-label Phase 2 BELIEVE

Zynerba Pharmaceuticals Inc told investors that an article in the  Journal of the American Medical Association (JAMA) Network Open had described the results of the company's open-label Phase 2 BELIEV

DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare

In a note to clients on August 20, Canaccord Genuity analysts reiterated their ‘Buy' rating and $9 target price on shares of Zynerba Pharmaceuticals Inc, saying “ZYNE stock presents a potentially

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape

Focused on treating rare epilepsies and neuropsychiatric disorders Lead candidate Zygel offers a goldmine of therapies for multiple conditions Initiating RECONNECT trial with Zygel for Fragile X syndr

Zynerba Pharmaceuticals Inc has posted second-quarter results with ample cash on hand, which gives the company a long runway to run pivotal trials of its flagship product Zygel (ZYN002), a patent-prot

DEVON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare

DEVON, Pa., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare